logo Orixha mobile logo Orixha

Cardiac arrest

A major public health issue

Out-of-hospital cardiac arrest is a major public health issue with an incidence of more than 6 per 10 000. Each year, more than 700 000 patients are affected by cardiac arrest in Europe or North America. Among all the cardiac arrest patients, only 30% of them are successfully resuscitated and transferred to intensive care units.

700.000
cardiac arrests each year in EU an North America

Unfortunately, survival rate is very low and about 70% of successfully resuscitated patients dies within few hours from neurological, cardiac and multi-visceral failure due to post-cardiac arrest syndrome.

Finally, survival rate in industrialized countries is less than 10% after out-of-hospital cardiac arrest.

Fighting the post-cardiac arrest syndrome

For the past decades, tremendous work has been done in order to improve the initial management of cardiac arrest patients and the succes rate of cardiopulmonary resuscitation. This could be achieved through large scale educational initiative for general public, development of public external defibrillators, etc. However, the management of successfully resuscitated patients is still a major issue. Neurological and systemic consequences of cardiac arrest are still extremely challenging to deal with.

Today, targeted temperature management at 33°C is the best strategy to reduce those injuries. It represents the corner stone of the management of succesfully resuscitated patients after cardiac arrest in ICU.

More and more experimental studies shows that therapeutic hypothermia is the most efficient when target temeprature is reached rapidly after cardiac arrest. A recent study confirms further these findings.

Ultra-rapid therapeutic hypothermia

Brain : 5min

Heart : 1min

Kidneys : 10min

Whole body : 30min

From 37°C to 33°C in 30 minutes

The technology developped by Orixha allows to dramatically increase the cooling speed of the patient in order to maximize the chances of good neurological recovery. This methods is drastically faster than other conventionnal approaches of hypothermia induction or targeted temperature management, which are only able to cool down a patient within 4 hours after resumption of spontaneous circulation.

Our modelisations are showing that LV4C should be able to induce whole body hypothermia in less than 30 min. Due to the use of the lungs as a heat exchangers, cooling is primarly acting on heart and brain, then highly perfused organs like kidneys before cooling down the whole body.

With this ultra-rapid cooling of all the critical organs but also by reaching the whole body hypothermic state, LV4C can mitigate efficiently the post-cardiac arrest syndrome and inflammatory storm occuring avec cardiopulmonary resuscitation.

In experimental settings, ultra-rapid induction of hypothermia by LV4C can increase up to 5 times the survival rate.